Exelixis, Inc. (EXEL) financial statements and ratios from SEC XBRL: revenue $2.32B (TTM), net margin 33.7%, revenue growth 10.6% YoY, P/E 15.5. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.32B |
| Net Margin | 33.7% |
| Revenue Growth (YoY) | 10.6% |
| EPS Growth (YoY) | 25.0% |
| FCF Growth (YoY) | 552.0% |
| P/E Ratio | 15.5 |
| EV / EBITDA | 13.0 |
| Price / Book | 7.21 |
| Price / Sales | 5.46 |
| FCF Yield | 8.8% |
| DCF Value (model) | $40.94 |
| DCF Upside vs Price | -23.7% |
| Altman Z-Score | 14.47 (safe) |
| Sector P/E (Healthcare) | 21.6 |
EXEL overview · EXEL earnings · EXEL KPIs · EXEL investor relations · EXEL ownership · EXEL peers · EXEL filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.